Why Palantir Stock Is a ‘Perfect' Buy for 2025
Palantir Technologies (PLTR) is a leading software company providing data analysis and decision-making solutions that leverage artificial intelligence (AI). Its products are Palantir Foundry, Palantir Gotham, Palantir Apollo, and Artificial Intelligence Platform (AIP), targeting both governments and commercial clients.
With a market capitalization of $182.7 billion, Palantir shot to fame alongside the AI surge, gaining a massive 950% since 2023 and 360% over the past 52 weeks.
Despite its success in recent years the stock appears to be struggling at the moment. Shares are up just 6.8% in the year to date and are trading almost 6% below their 52-week high of $84.80 set last week on Jan. 24.
Palantir Is the 'Perfect' Stock
Investor's Business Daily has published a list of 28 so-called 'perfect' stocks. The list features artificial intelligence heavyweights like Nvidia (NVDA), Arista Networks (ANET), Meta Platforms (META), and more. In addition to AI stocks, it also has Netflix (NFLX), Duolingo (DUOL), Olo (OLO), and Marex (MRX).
A total of 7 conditions were set for inclusion on the list. Companies had to have a current share price of $12 or higher and a 50-day average trading volume of more than 400,000 shares. Additionally, they had to score above certain thresholds in categories like earnings per share and relative strength.
Palantir Beats Estimates
Palantir released its third-quarter results last year on Nov. 4. Its profit of $144 million translated to $0.06 per share, and its adjusted earnings per share came in at $0.10. This beat the analyst estimate of $0.09 per share. The company saw revenue rise 30% year-over-year to $725.5 million, beating the analyst estimate of $703.7 million.
The AI company's EBITDA was $283.6 million, against analysts' $244.9 million estimate. Its EBITDA margin increased to 39.1% from 30.8% reported in the same quarter last year. GAAP gross margin remained unchanged at 79.8%. Its cash and cash equivalents balance dipped to $768 million from the $831 million reported at the end of 2023, but its free cash flow margin shot up to 60%.
Management also hiked their outlook for 2024 with revenue now expected between $2.805 billion to $2.809 billion with adjusted income from operations to be between $1.054 billion and $1.058 billion. Free cash flow guidance is hiked to more than $1 billion.
For the ongoing Q4, Palantir anticipates revenue in the range of $767 million to $771 million while adjusted income from operations is anticipated between $298 million and $302 million.
Palantir is set to release its fourth-quarter results after the market closes on Feb. 3, 2025.
Analysts' Take on PLTR Stock
Palantir's surge in the recent past has left analysts chasing after the stock. The stock has a consensus 'Hold' rating with a mean price of $47.29, signifying downside potential of 40%. Shares are trading far above the average price target, although the Street-high price target of $90 represents 12.5% upside potential.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Why Palantir Stock Soared in May
Shares of Palantir Technologies (NASDAQ: PLTR) were up in May. The company's stock finished the month up 11.3%. The move came as the S&P 500 (SNPINDEX: ^GSPC) was up 5.5% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) was up 7.9% during the month. The artificial intelligence (AI)-powered data analytics company released mostly positive earnings and announced several key new partnerships, and CEO Alex Karp accompanied President Trump on a trip to Saudi Arabia. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » A mostly positive quarter Palantir reported Q1 earnings per share (EPS) of $0.13 on sales of $884 million. That revenue figure was up 39% year over year (YOY), beating Wall Street expectations. There was some cause for concern, however, as global sales declined 10% YOY. Karp goes to Saudi Arabia Given this international weakness, the timing of Karp's trip to Saudi Arabia could not have been better. Karp, along with other high-profile CEOs, accompanied President Trump on a trip to the Middle Eastern country. The trip ended with Trump announcing that Saudi Arabia had committed to $600 billion in investments and, although specifics were light, some of this is likely to flow into Palantir's coffers. New partnerships Palantir announced new partnerships with xAI, the Joint Commission, and the manufacturer Fedrigoni. The partnerships will all leverage the company's unique capabilities to boost efficiency, maximize profits, and reshape outdated business practices. The wide range of distinct organizations and problems shows the incredible adaptability of Palantir's technology. Beware the valuation This is nothing new for investors who have followed the company at all, but the fact is that Palantir stock is incredibly expensive. The company's price-to-earnings ratio (P/E) currently sits north of 570. Its price-to-sales ratio (P/S) is 105. These are astronomical numbers. Consider this: When Nvidia was seeing peak growth in 2024 -- growth that far outstrips what Palantir is delivering today -- the chipmaker's P/E and P/S were both roughly half that of Palantir's. And when Cisco was at its peak in 2000, before it became the face of the dot-com crash, it too only reached roughly half the valuation that Palantir now carries. I do not believe Palantir can justify this valuation, and it is a matter of time before the stock comes back to Earth. Although it's clear that the company offers an extremely valuable product, I think it's fair to classify it as a meme stock at this point: Too much of its value is driven by pure hype. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor 's total average return is999% — a market-crushing outperformance compared to173%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Cision Canada
a day ago
- Cision Canada
Phoenix Aviation Capital and AIP Capital Announce Closing of $300m Senior Secured Credit Facility
Expands Lender Relationships to Further Support Platform's Growth DUBLIN and STAMFORD, Conn. and NEW YORK, June 10, 2025 /CNW/ -- Phoenix Aviation Capital ("Phoenix" or "the Company"), a full-service aircraft lessor managed by AIP Capital ("AIP") and a portfolio company of funds advised or controlled by affiliates of BC Partners Advisors L.P. announced the closing of a $300 million senior secured credit facility ("the facility"). Royal Bank of Canada ("RBC") acted as Structured Agent. RBC, Citibank and Morgan Stanley acted as Joint Lead Arrangers. The facility will be used to refinance seven assets currently owned by Phoenix and provide future funding for new asset acquisitions. "This facility represents another key milestone in Phoenix's expansion of its lender group and availability of debt capital," said Jared Ailstock, Managing Partner at AIP. "We are grateful for the support from the bank group as we continue to execute on Phoenix's growth strategy." "Closing this facility through a combination of new lenders and existing banks demonstrates the support Phoenix and AIP have in the aviation bank market," said Patrick Schafer, Managing Director at BC Partners and board member of Phoenix. "The facility will provide Phoenix with additional capacity and flexibility to support the Company's airline customers." Vedder Price served as transaction counsel and PwC acted as tax advisor to Phoenix and AIP. McCann Fitzgerald also acted in capacity as Irish counsel to Phoenix and AIP. Clifford Chance served as transaction counsel to the lenders. About AIP Capital AIP Capital (AIP) is a global alternative investment manager focused on opportunities in asset-based finance including aviation and equipment finance. AIP, together with its affiliates, manages approximately $4 billion of assets on behalf of a diversified global investor base. The AIP team is comprised of more than 30 experienced professionals across AIP's offices in Stamford, New York City, Dublin, and Singapore. For more information about AIP Capital or to speak with company executives, please contact [email protected]. BC Partners is a leading international investment firm in private equity, private debt, and real estate strategies. BC Partners Credit was launched in February 2017, with a focus on identifying attractive credit opportunities in any market environment, often in complex market segments. The platform leverages the broader firm's deep industry and operating resources to provide flexible financing solutions to middle-market companies across Business Services, Industrials, Healthcare and other select sectors. For further information, visit Media Contacts AIP Capital Geoffrey Bayers [email protected] BC Partners Luke Charalambous [email protected] +44 7775 180 721 SOURCE AIP Capital
Globe and Mail
2 days ago
- Globe and Mail
Analysts Say AI Could Add $100B+ to Healthcare—But Most Systems Aren't Ready
Issued on behalf of Avant Technologies Inc. VANCOUVER – News Commentary – A growing chorus of political and academic voices is calling AI the defining force behind the next evolution in healthcare. Former UK Prime Minister Tony Blair recently warned that failing to embrace AI-driven doctors and nurses could leave entire nations behind, while London Business School professor Nicos Savva echoed the sentiment in Forbes, framing AI as essential to future-ready care. Meanwhile, a new Wolters Kluwer report highlights a troubling disconnect: while interest is surging, most healthcare organizations remain unprepared to deploy GenAI tools at scale. Yet even as institutions scramble to catch up, key breakthroughs are already coming from innovators like Avant Technologies, Inc. (OTCQB: AVAI), Palantir Technologies (NASDAQ: PLTR), Astrana Health, Inc. (NASDAQ: ASTH), Tempus AI, Inc. (NASDAQ: TEM), and SoundHound AI, Inc. (NASDAQ: SOUN). Analysts at McKinsey now estimate that generative AI could generate up to $110 billion in annual value across pharma and medical products alone. Statista projects the broader AI healthcare market will surge from $11 billion today to $188 billion by 2030 — a leap that signals just how quickly the landscape is changing. Avant Technologies, Inc. (OTCQB: AVAI) has just taken a major step forward in its evolution from AI incubator to full-stack healthcare innovator. Today, the company announced it had signed a non-binding letter of intent to acquire 100% of Ainnova Tech, its joint venture partner and the developer of the Vision AI diagnostic platform. Prior to the acquisition, the two companies have been operating jointly through Ai-nova Acquisition Corp (AAC), which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments. 'We believe bringing the two companies together will offer tremendous value for shareholders, it will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally,' said Vinicio Vargas, CEO at Ainnova and a member of the Board of Directors of AAC. 'We feel the joint venture has been a success and both companies have worked well together toward a common goal, so we believe that we can be even more successful and use our resources more effectively as one company to further AI in healthcare.' Under the proposed agreement, Ainnova would roll all of its outstanding equity into the combined public entity — unifying leadership and eliminating structural complexity ahead of a scheduled FDA pre-submission meeting in July. While final terms of the deal are still being negotiated, both companies say the merger would streamline commercialization and accelerate the rollout of Ainnova's flagship Vision AI technology — a platform already in use across clinical sites in Latin America for the early detection of diabetic retinopathy, cardiovascular disease, and other chronic conditions. The move also signals growing confidence from Avant's leadership as they prepare to bring proprietary hardware into the mix. In parallel with the merger discussions, Avant and Ainnova are entering the final prototyping stage of a low-cost, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel. The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics. 'The cost of a fundus camera has always been a barrier to entry in this market,' said Vargas. 'Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market.' Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare. 'Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily,' said Vargas in a previous statement. 'We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions.' As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care. Palantir Technologies (NASDAQ: PLTR) has partnered with TeleTracking Technologies to bring real-time AI-driven insights to hospitals and health systems. 'This partnership with TeleTracking represents the AI revolution in healthcare we are in the midst of—where we continue to move closer to a world where all hospitals and health systems are embracing, implementing and operating with an AI-powered approach,' said Alex Karp, CEO at Palantir. 'Helping to streamline operations allowing for increased focus on providing the best level of care.' By integrating TeleTracking's Operations IQ platform with Palantir's Foundry and AIP tools, the collaboration will enable smarter resource management, predictive forecasting, and near-instant operational decision-making. The combined platform is designed to improve patient flow, reduce staff burden, and drive measurable gains in both care outcomes and financial performance. Astrana Health, Inc. (NASDAQ: ASTH) recently announced a wave of leadership appointments as the company accelerates its national rollout of an AI-driven, value-based care model. The most notable addition is Sherry McBride, a seasoned Medicare Advantage operator who joins as COO to lead integration and execution across Astrana's growing platform. 'We are thrilled to welcome Sherry, along with other recent executive hires and promotions, to the leadership team at a time of immense growth and opportunity for Astrana,' said Brandon Sim, President and CEO of Astrana Health. 'Her deep experience in delegated value-based care will further strengthen our ability to drive consistent, coordinated, high-quality patient outcomes at scale.' Other hires include a new Chief Data and Analytics Officer, Chief Accounting Officer, and Chief People Officer — a signal of Astrana's broader push to deepen capabilities across every operational tier. With a footprint spanning over 12,000 providers and more than a million patients, Astrana is preparing to scale smart, coordinated care on a national level. Tempus AI, Inc. (NASDAQ: TEM) has expanded its generative AI clinical assistant, Tempus One, with direct integration into EHR systems, allowing physicians to query data and streamline workflows in real time. 'As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.' The platform now includes embedded ASCO guidelines, appointment prep tools, and intelligent note-taking — reducing administrative burden and improving decision-making in oncology and beyond. Tempus is also rolling out its Agent Builder tool to select providers, enabling custom GenAI solutions integrated directly into clinical practice. SoundHound AI, Inc. (NASDAQ: SOUN) has partnered with Allina Health to launch 'Alli,' an AI-powered voice agent designed to streamline patient access and reduce administrative bottlenecks. "One of our key goals is to make sure that we're providing a market-leading patient experience," said David Ingham, DO, Chief Information Officer of Allina Health. "Alli is an extension of our team, and we're excited to have her on board to streamline operations, reduce wait times, and deliver a faster, more seamless experience for our patients." Built on the Amelia conversational AI platform, Alli integrates with Allina's EHR system to authenticate callers, manage appointments, and soon handle tasks like refilling medications or answering non-clinical questions. "Long wait times and administrative complexity can be a huge source of stress for patients," said Michael Anderson, Executive Vice President of Enterprise AI at SoundHound AI. "We are proud to partner with Allina Health on this important digital transformation. The organization is taking a forward-thinking approach by integrating AI to support patients with immediate, personalized assistance." Early results show improved call efficiency and faster response times, enabling staff to focus on complex patient needs. CONTACT: cs@ (250) 999-4849 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of Media Corp. ('BAY') BAY has been not been paid a fee for Avant Technologies Inc. advertising and/or digital media, but the owner(s) of BAY also own Market IQ Media Group, Inc., which has been paid a fee from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Avant Technologies Inc. which were purchased in the open market. BAY and all of it's respective employees, owners and affiliates reserve the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by BAY has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
